。7 Polysaccharide-K ·8 Research .8.3 Anti-GD2 antibodies History oy for th r has bee nt of infection in the desired location and cause regression of the tumour.In 13th century,St.Peregrine experienced spontaneous regression of tumor,after the tumor became infected.In the 18th and 19th centuries,deliberate were a stand wounds were left ope French physician Dusso y so o品洁n的 posing the tumor to infection includin there sea relationship between infection and cancer regression date back to at least the 1th Modern Immunotherapy began in 1796 when Edward Jenner produced the first vaccine involving immunisation with cowpox to prevent smallpox.Towards the end of the 19th century Emil von Behring and Shibasaburo Kitasato discovered that injecting animals with diphtheria toxin produced blood serum with antitoxins to i provoking ar acioraphgtobadeia.h1968apmoleinrehidohiseg was identified and calle in prod rapy for cancer was introduced by Ste 厂oc or regres ate (2. 33%)in 1205 patients with metastatic cancer who underwent In 1987,rese archers identified cytotoxic T-lymphocyte antigen 4,or CTLA-4.Allison found that CTLA-4 prevents cks tumo 00 CTLA WOU the immune rs in In 1999 b ch firm Med hts to the dy In 2010 Bristol-Myers Squibb,who acquired Medarex in 2009,reported that patients with metastatic melanoma lived ded life in advanced melanoma in a randomized trial.st tme any treatme an average of 10 months on the antibody,versus 6 month: In the early 1990s,a biologist discovered a molecule expressed in dying T cells,which he called programmed bler of T cells.An antibody that targeted PD-1 was remission in multiple subjects across multiple cancer types.In 2013